利奈唑胺对艰难梭菌的体外活性。
In vitro activity of linezolid against Clostridium difficile.
作者信息
Peláez T, Alonso R, Pérez C, Alcalá L, Cuevas O, Bouza E
机构信息
Microbiology and Infectious Diseases Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2002 May;46(5):1617-8. doi: 10.1128/AAC.46.5.1617-1618.2002.
Abstract
We examined the in vitro activity of linezolid against Clostridium difficile, including isolates with reduced susceptibility to metronidazole or vancomycin. The MIC at which 50% of the isolates were inhibited (MIC50) and MIC90 were 0.5 and 2 microg/ml, respectively (range, 0.03 to 4 microg/ml). MICs were always <or= 4 microg/ml, and thus, all isolates were considered susceptible.
摘要
我们检测了利奈唑胺对艰难梭菌的体外活性，包括对甲硝唑或万古霉素敏感性降低的分离株。50%的分离株被抑制时的最低抑菌浓度（MIC50）和MIC90分别为0.5和2微克/毫升（范围为0.03至4微克/毫升）。MIC值始终≤4微克/毫升，因此，所有分离株均被视为敏感。
相似文献
1
In vitro activity of linezolid against Clostridium difficile.利奈唑胺对艰难梭菌的体外活性。
Antimicrob Agents Chemother. 2002 May;46(5):1617-8. doi: 10.1128/AAC.46.5.1617-1618.2002.
2
In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.体外和体内抗菌评估卡他唑，一种新的抗生素治疗艰难梭菌感染。
Antimicrob Agents Chemother. 2014;58(2):892-900. doi: 10.1128/AAC.01830-13. Epub 2013 Nov 25.
3
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.艰难梭菌对甲硝唑和万古霉素敏感性的重新评估。
Antimicrob Agents Chemother. 2002 Jun;46(6):1647-50. doi: 10.1128/AAC.46.6.1647-1650.2002.
4
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.雷莫拉宁、替考拉宁、万古霉素、利奈唑胺、杆菌肽及其他四种抗菌药物对肠道厌氧菌的体外活性
Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8. doi: 10.1128/AAC.47.7.2334-2338.2003.
5
Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.分析单独及联合使用时，短小杆菌素 CD、万古霉素、甲硝唑、瑞他莫林和 actagardine 对艰难梭菌的抑制活性。
Antimicrob Agents Chemother. 2013 Jun;57(6):2882-6. doi: 10.1128/AAC.00261-13. Epub 2013 Apr 9.
6
In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.达托霉素、利奈唑胺和奎奴普丁-达福普汀对包括万古霉素中介金黄色葡萄球菌和万古霉素耐药粪肠球菌在内的葡萄球菌和肠球菌挑战组的体外活性。
Microb Drug Resist. 2003 Winter;9(4):389-93. doi: 10.1089/107662903322762833.
7
In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.新型酮内酯 RBx 14255 对艰难梭菌的体外和体内活性。
Antimicrob Agents Chemother. 2012 Nov;56(11):5986-9. doi: 10.1128/AAC.00015-12. Epub 2012 Aug 6.
8
Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.1991年和1997年在法国分离出的艰难梭菌临床菌株的抗菌药敏性及血清群
Antimicrob Agents Chemother. 1999 Nov;43(11):2607-11. doi: 10.1128/AAC.43.11.2607.
9
E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.对医院内艰难梭菌分离株进行E试验药敏试验，检测其对甲硝唑、万古霉素、夫西地酸以及新型药物莫西沙星、加替沙星和利奈唑胺的敏感性。
Eur J Clin Microbiol Infect Dis. 2002 Jan;21(1):72-4. doi: 10.1007/s10096-001-0658-0.
10
In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.体外研究 CB-183,315、万古霉素和甲硝唑对 556 株艰难梭菌、445 株其他肠道厌氧菌和 56 株肠杆菌科细菌的活性。
Antimicrob Agents Chemother. 2012 Mar;56(3):1613-5. doi: 10.1128/AAC.05655-11. Epub 2011 Dec 19.
引用本文的文献
1
Characterization of High-Linezolid-MIC Isolated from a Chinese Hospital: First Genomic Evidence of (B) Transmission and Tn Association.从一家中国医院分离出的高利奈唑胺最低抑菌浓度菌株的特征：（B）传播和转座子关联的首个基因组证据
Infect Drug Resist. 2025 Sep 8;18:4789-4798. doi: 10.2147/IDR.S523333. eCollection 2025.
2
Phenotypical and Genotypical Comparison of Isolated from Clinical Samples: Homebrew DNA Fingerprinting versus Antibiotic Susceptibility Testing (AST) and Clostridial Toxin Genes.从临床样本中分离出的菌株的表型和基因型比较：自制DNA指纹图谱与抗生素敏感性测试（AST）及梭菌毒素基因
Can J Infect Dis Med Microbiol. 2021 Dec 2;2021:7386554. doi: 10.1155/2021/7386554. eCollection 2021.
3
Mobile Oxazolidinone Resistance Genes in Gram-Positive and Gram-Negative Bacteria.革兰阳性菌和革兰阴性菌中的移动恶唑烷酮类耐药基因。
Clin Microbiol Rev. 2021 Jun 16;34(3):e0018820. doi: 10.1128/CMR.00188-20. Epub 2021 Jun 2.
4
Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait.科威特5年期间医院和社区获得性产毒艰难梭菌分离株的抗生素耐药性监测
PLoS One. 2016 Aug 18;11(8):e0161411. doi: 10.1371/journal.pone.0161411. eCollection 2016.
5
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.艰难梭菌的抗药性和耐药性降低：对艰难梭菌感染的诱导、治疗和复发的潜在影响。
Antibiotics (Basel). 2015 Jul 10;4(3):267-98. doi: 10.3390/antibiotics4030267.
6
Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.伊朗艰难梭菌临床分离株的抗菌药敏性
Iran Red Crescent Med J. 2013 Aug;15(8):704-11. doi: 10.5812/ircmj.5189. Epub 2013 Aug 5.
本文引用的文献
1
In vitro activity of linezolid and eperezolid against anaerobic bacteria.
Clin Microbiol Infect. 1999 Jan;5(1):51-53. doi: 10.1111/j.1469-0691.1999.tb00099.x.
2
Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.健康受试者口服[(14)C]利奈唑胺后的药代动力学、代谢及排泄情况。
Drug Metab Dispos. 2001 Aug;29(8):1136-45.
3
"Second-look" cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD.“二次观察”细胞毒性：艰难梭菌分离株培养加细胞毒素检测在艰难梭菌相关性腹泻实验室诊断中的评估
J Hosp Infect. 2001 Jul;48(3):233-7. doi: 10.1053/jhin.2001.1000.
4
Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea.HIV阳性且反复发生艰难梭菌相关性腹泻患者复发与再感染的分子分析
J Hosp Infect. 2001 Jun;48(2):86-92. doi: 10.1053/jhin.2001.0943.
5
Linezolid: a review of its use in the management of serious gram-positive infections.利奈唑胺：用于严重革兰氏阳性菌感染治疗的综述
Drugs. 2001;61(4):525-51. doi: 10.2165/00003495-200161040-00008.
6
Linezolid: an oxazolidinone antimicrobial agent.利奈唑胺：一种恶唑烷酮类抗菌药物。
Clin Ther. 2001 Mar;23(3):356-91. doi: 10.1016/s0149-2918(01)80043-6.
7
In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods.
Diagn Microbiol Infect Dis. 2001 Jan;39(1):49-53. doi: 10.1016/s0732-8893(00)00210-8.
8
In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.利奈唑胺对多重耐药革兰氏阳性临床分离株的体外活性。
J Antimicrob Chemother. 2001 Jan;47(1):77-81. doi: 10.1093/jac/47.1.77.
9
In vitro and in vivo activities of nitazoxanide against Clostridium difficile.硝唑尼特对艰难梭菌的体外和体内活性
Antimicrob Agents Chemother. 2000 Sep;44(9):2254-8. doi: 10.1128/AAC.44.9.2254-2258.2000.
10
["Second look" at cytotoxin B of Clostridium difficile in the course of diarrhea associated with antibiotic therapy].艰难梭菌细胞毒素B在抗生素治疗相关腹泻病程中的“二次观察”
Pathol Biol (Paris). 1999 May;47(5):415-21.
Zotero 插件